Catalent, Inc. ( CTLT ) Nowojorska Giełda Papierów Wartościowych

Cena: 63.48 ( 0.0% )

Aktualizacja 12-17 22:00
Nowojorska Giełda Papierów Wartościowych
Branża: Drug Manufacturers - Specialty & Generic
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:
An error occurred: DataFrame is empty. Check the ticker or date range.

Informacje o spółce:
Sektor: Zdrowie
Branża: Drug Manufacturers - Specialty & Generic
Zatrudnienie: 17 000
Giełda: Nowojorska Giełda Papierów Wartościowych
Ilość akcji w obrocie: 97%
Ilość akcji: 180 738 000
Debiut giełdowy: 2014-07-31
WWW: https://www.catalent.com
CEO: Mr. Alessandro Maselli
Adres: 14 Schoolhouse Road
Siedziba: 08873 Somerset
ISIN: US1488061029
Opis firmy:

Catalent, Inc., wraz z spółkami zależnymi, opracowuje i produkuje roztwory leków, biologii biologicznej, komórek i genów oraz produktów zdrowotnych konsumenckich na całym świecie. Działa w czterech segmentach: biologiczne, softgel i technologie ustne, dostarczanie ustne i specjalistyczne oraz usługi podaży klinicznej. Segment softgel i technologii doustnych zapewnia usługi preparatów, rozwoju i produkcji dla miękkich kapsułek do stosowania w różnych produktach klientów, takich jak leki na receptę, leki bez recepty, suplementy diety, kosmetyki jednostek dawki i preparaty lecznicze w zakresie zdrowia zwierząt. Segment biologiczny zapewnia biologiczną linię komórkową; rozwija i produkuje terapię komórkową i wirusową terapię genową; sformułowanie, rozwój i produkcja dla dawek pozajelitowych, w tym fiolki, prefilowane strzykawki, fiolek i naboje; oraz usługi rozwoju i testowania analitycznego. Segment dostawy jamy ustnej i specjalistycznej oferuje sformułowanie, rozwój i produkcję w różnych technologiach, a także zintegrowane dalsze rozwój kliniczny i roztwory dostaw komercyjnych. Ten segment oferuje również platformę doustnych rozwiązań do dostarczania obejmująca przedkliniczne badania przesiewowe, formułowanie, rozwój analityczny i aktualne usługi dobrych praktyk produkcyjnych. Segment usług dostaw klinicznych oferuje produkcję, opakowanie, przechowywanie, dystrybucję i zarządzanie zapasami w badaniach klinicznych leków i biologicznych. Oferuje również usługi podaży klinicznej kierowanej przez popyt. Firma obsługuje firmy farmaceutyczne, biotechnologii i zdrowia konsumenckiego; oraz firmy z innych segmentów rynku opieki zdrowotnej, takie jak zdrowie zwierząt i urządzenia medyczne, a także w branżach kosmetyków. Catalent, Inc. został zarejestrowany w 2007 roku i ma siedzibę w Somerset w stanie New Jersey.

Wskaźniki finansowe
Kapitalizacja (USD) 11 522 381 760
Aktywa: 9 708 000 000
Cena: 63.48
Wskaźnik Altman Z-Score: 1.6
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -27.8
Ilość akcji w obrocie: 97%
Średni wolumen: 2 268 467
Ilość akcji 181 512 000
Wskaźniki finansowe
Przychody TTM 4 422 000 000
Zobowiązania: 6 166 000 000
Przedział 52 tyg.: 42.11 - 63.5
Piotroski F-Score: 4
Umiarkowany (średnia jakość finansowa)
EPS: -2.3
P/E branży: 21.3
Beta: 1.158
Raport okresowy: 2025-02-07
WWW: https://www.catalent.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Aristippos Gennadios Ph.D. Group President of Pharma & Consumer Health Segment 799 263 1966
Mr. Ricky Hopson President, Division Head for BioProduct Delivery & Chief of Staff 622 125 1977
Mr. John J. Greisch M.B.A. Executive Chairman of the Board 125 907 1955
Mr. Alessandro Maselli President, Chief Executive Officer & Director 1 083 437 1972
Mr. Michael J. Grippo Senior Vice President of Strategy & Corporate Development 0 1969
Mr. Michael J. Hatzfeld Jr. Vice President & Chief Accounting Officer 0 1973
Mr. Joseph A. Ferraro J.D. Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary 0 1978
Mr. Matti M. Masanovich Senior Vice President & Chief Financial Officer 0 1972
Mr. Charles Lickfold Senior Vice President & Chief Information Officer 0 1974
Mr. Paul Surdez Vice President of Investor Relations 0 0
Wiadomości dla Catalent, Inc.
Tytuł Treść Źródło Aktualizacja Link
Prolific Machines Appoints Former Catalent Chief Scientific Officer to Board of Directors EMERYVILLE, Calif.--(BUSINESS WIRE)--Prolific Machines announces appointment of Julien Meissonnier, former Chief Scientific Officer of Catalent, to its Board as an Independent Director. businesswire.com 2025-05-15 12:00:00 Czytaj oryginał (ang.)
Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI Lisata Therapeutics Inc earlier this week discussed the potential of certepetide in antibody-drug conjugate (ADC) applications through a new collaboration with Catalent. The company told investors that it entered a research license agreement with Catalent to evaluate certepetide as a payload in SMARTag dual-payload ADCs. proactiveinvestors.com 2025-04-19 14:56:26 Czytaj oryginał (ang.)
Lisata Therapeutics signs research license with Catalent Lisata Therapeutics Inc (NASDAQ:LSTA) announced that it has entered into a research license agreement with Catalent to evaluate certepetide, its iRGD cyclic peptide candidate, using Catalent's SMARTag antibody-drug conjugate (ADC) platform. The research will focus on preclinical testing for diseases such as advanced solid tumors. proactiveinvestors.com 2025-04-15 13:17:16 Czytaj oryginał (ang.)
Lisata Therapeutics Announces Research License with Catalent BASKING RIDGE, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company has entered into a research license with Catalent, Inc. (“Catalent”) to evaluate, in a preclinical setting, the efficacy of Lisata's iRGD cyclic peptide product candidate, certepetide, as a payload used in the context of Catalent's SMARTag® antibody-drug conjugate (“ADC”) dual-payload technology platform for the treatment of difficult-to-treat-diseases, including advanced solid tumors. globenewswire.com 2025-04-15 12:00:00 Czytaj oryginał (ang.)
Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the investment firm said, as it prepares for a likely focus on U.S. manufacturing by President-elect Donald Trump. reuters.com 2025-01-16 16:24:48 Czytaj oryginał (ang.)
Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400 NEW YORK , Dec. 18, 2024 /PRNewswire/ -- S&P MidCap 400 constituent Lennox International Inc. (NYSE: LII) will replace Catalent Inc. (NYSE: CTLT) in the S&P 500, and BILL Holdings Inc. (NYSE: BILL) will replace Lennox International in the S&P MidCap 400 effective prior to the opening of trading on Monday, December 23. Novo Holdings A/S has acquired Catalent in a deal that closed today, December 18. prnewswire.com 2024-12-18 19:46:00 Czytaj oryginał (ang.)
Novo Holdings completes $16.5 bln takeover of Catalent Novo Holdings has completed its $16.5 billion takeover of Catalent , the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfilled. reuters.com 2024-12-18 11:08:43 Czytaj oryginał (ang.)
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days. reuters.com 2024-12-14 13:53:42 Czytaj oryginał (ang.)
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S's pending acquisition of Catalent, Inc. (Catalent), including expiry of the timing agreement in the US, have been fulfilled. Catalent is a global contract development and manufacturing organisation headquartered in New Jersey (US). The parties are now free to close the transaction, as well as Novo Nordisk's subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S. globenewswire.com 2024-12-14 02:08:00 Czytaj oryginał (ang.)
Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that the companies have fulfilled all regulatory closing conditions for their pending transaction. The companies now expect to close the transaction in the coming days. “Today represents an important step in our t. businesswire.com 2024-12-14 02:06:00 Czytaj oryginał (ang.)
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S' acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US), as well as Novo Nordisk's subsequent acquisition of three manufacturing sites from Novo Holdings A/S. globenewswire.com 2024-12-06 15:11:00 Czytaj oryginał (ang.)
Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that the European Commission (EC) has granted unconditional approval for the pending transaction under which Novo Holdings will acquire Catalent. “We are pleased to have received European Commission approval, whic. businesswire.com 2024-12-06 15:08:00 Czytaj oryginał (ang.)
Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any competition issues. reuters.com 2024-12-06 15:05:07 Czytaj oryginał (ang.)
Why Is Catalent (CTLT) Up 3.2% Since Last Earnings Report? Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? zacks.com 2024-12-05 14:35:57 Czytaj oryginał (ang.)
EU antitrust regulators set to okay $16.5 bln Novo Holdings, Catalent deal, source says EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent , a person with direct knowledge of the matter said on Friday. reuters.com 2024-11-22 14:37:40 Czytaj oryginał (ang.)
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' planned $16.5 billion takeover of Catalent , people familiar with the matter said. reuters.com 2024-11-13 14:43:13 Czytaj oryginał (ang.)
JAZZ or CTLT: Which Is the Better Value Stock Right Now? Investors interested in Medical - Drugs stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two stocks is more attractive to value investors? zacks.com 2024-11-13 14:40:22 Czytaj oryginał (ang.)
Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours trading. zacks.com 2024-11-06 12:11:01 Czytaj oryginał (ang.)
Catalent (CTLT) Reports Q1 Loss, Lags Revenue Estimates Catalent (CTLT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.11. This compares to loss of $0.10 per share a year ago. zacks.com 2024-11-05 11:25:21 Czytaj oryginał (ang.)
Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday. reuters.com 2024-11-05 10:25:33 Czytaj oryginał (ang.)
EU antitrust regulators to decide on Novo's Catalent buy by Dec. 6 EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of contract drug manufacturer Catalent , according to a filing on the European Commission website on Monday. reuters.com 2024-11-04 05:01:29 Czytaj oryginał (ang.)
CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the acquisition, especially in weight-loss drug manufacturing. zacks.com 2024-10-24 16:10:21 Czytaj oryginał (ang.)
Roche comes out against clearing takeover of drug manufacturer Catalent The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by Novo Nordisk's controlling shareholder, citing harm to industry peers. reuters.com 2024-10-23 08:41:10 Czytaj oryginał (ang.)
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk. reuters.com 2024-10-21 11:31:01 Czytaj oryginał (ang.)
Consumer groups ask FTC to block Novo Holdings-Catalent deal Five U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Nordisk's controlling shareholder from acquiring contract drug manufacturer Catalent , saying the deal threatens competition in weight loss drugs and cutting-edge gene therapies. reuters.com 2024-10-17 18:03:29 Czytaj oryginał (ang.)